Naturally occurring earthquakes
Tectonic earthquakes occur anywhere in the earth where there is sufficient stored elastic strain energy to drive fracture propagation along a fault plane. The sides of a fault move past each other smoothly and aseismically only if there are no irregularities or asperities along the fault surface that increase the frictional resistance. Most fault surfaces do have such asperities, which leads to a form of stick-slip behavior. Once the fault has locked, continued relative motion between the plates leads to increasing stress and, therefore, stored strain energy in the volume around the fault surface. This continues until the stress has risen sufficiently to break through the asperity, suddenly allowing sliding over the locked portion of the fault, releasing the stored energy. This energy is released as a combination of radiated elastic strain seismic waves, frictional heating of the fault surface, and cracking of the rock, thus causing an earthquake. This process of gradual build-up of strain and stress punctuated by occasional sudden earthquake failure is referred to as the elastic-rebound theory. It is estimated that only 10 percent or less of an earthquakes total energy is radiated as seismic energy. Most of the earthquakes energy is used to power the earthquake fracture growth or is converted into heat generated by friction. Therefore, earthquakes lower the Earths available elastic potential energy and raise its temperature, though these changes are negligible compared to the conductive and convective flow of heat out from the Earths deep interior.
The FDA lists the following:For subjects with chronic idiopathic constipation taking Amitiza:

Nausea ~ 29% (4% were severe, and 9% of patients discontinued treatment due to nausea. The rate of nausea was lower among male (8%) and elderly (19%) patients. No patients in the clinical studies were hospitalized due to nausea.) Diarrhea: ~12%  (2% were severe, and 2% of patients discontinued treatment due to diarrhea)
Several less common adverse reactions (<1%).For opioid-induced constipation:

Nausea: ~ 11%; 1% severe nausea and 2% discontinued treatment due to nausea. Diarrhea: ~ 8%; 2% severe diarrhea and 1% of patients discontinued treatment due to diarrhea. Less common adverse reactions (<1%): fecal incontinence, blood potassium decreased.For subjects with irritable bowel syndrome with constipation:

Nausea: ~ 8%; 1% severe nausea and 1% discontinued treatment due to nausea. Diarrhea: ~ 7%; <1% of patients had severe diarrhea and <1% of patients discontinued treatment due to diarrhea. Less common adverse reactions: <1%A 2018 pooled analysis from three phase III, randomized, double-blind, placebo-controlled studies on usage for Opioid-Induced Constipation, found that the numbers of patients reporting adverse effects were similar in both the lubiprostone and placebo treatment groups for all opioid classes (P ≥ 0.125); however, gastrointestinal adverse effects were reported more frequently by those receiving lubiprostone than 2 of the 3 opioid groups. The most commonly reported TEAEs in the lubiprostone treatment groups were nausea (13.4%–18.1%), diarrhea (1.2%–13.9%), and abdominal pain (4.7%–5.6%).